Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2—breast cancer

Fig. 1

METTL3 is silenced in HR+HER2− BC samples and cell lines. A The expression of m6A-related genes in the GSE87455 BC cohort. B and C The protein and mRNA levels of METTL3 in paired HR+HER2− BC tissues obtained before and after chemotherapy treatment. D The protein level of METTL3 in MCF-7 and MCF-7/ADR cell lines. E and F The mRNA and protein levels of METTL3 in MCF-7 and T47D cells treated with different concentrations DOX for 24 h and their corresponding control cells. G and H Upregulation of METTL3 expression was significantly associated with longer OS and RFS in HR+HER2− BC patients

Back to article page